{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sitagliptin+Placebo", "query": { "intervention": "Sitagliptin Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 99, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sitagliptin+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T21:56:22.279Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01488279", "title": "Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pre-diabetes", "Impaired Fasting Glucose", "Impaired Glucose Tolerance" ], "interventions": [ { "name": "Dexamethasone 2.5 mg and Sitagliptin 100 mg", "type": "DRUG" }, { "name": "Dexamethasone 2.5 mg and placebo tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Vermont", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2012-09", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2018-03-12", "last_synced_at": "2026-09-04T21:56:22.279Z", "location_count": 1, "location_summary": "South Burlington, Vermont", "locations": [ { "city": "South Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT01488279" }, { "nct_id": "NCT02111096", "title": "A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "LY2409021", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Sulfonylurea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 174, "start_date": "2014-04", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2019-10-09", "last_synced_at": "2026-09-04T21:56:22.279Z", "location_count": 26, "location_summary": "Concord, California • Fresno, California • Los Angeles, California + 19 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02111096" }, { "nct_id": "NCT00637273", "title": "A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "exenatide once weekly", "type": "DRUG" }, { "name": "sitagliptin", "type": "DRUG" }, { "name": "pioglitazone", "type": "DRUG" }, { "name": "placebo tablet", "type": "DRUG" }, { "name": "placebo once weekly", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 514, "start_date": "2008-01", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2015-04-07", "last_synced_at": "2026-09-04T21:56:22.279Z", "location_count": 51, "location_summary": "Peoria, Arizona • Artesia, California • Concord, California + 48 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Artesia", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00637273" }, { "nct_id": "NCT01907854", "title": "Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "liraglutide", "type": "DRUG" }, { "name": "sitagliptin", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 407, "start_date": "2013-12-02", "completion_date": "2015-06-15", "has_results": true, "last_update_posted_date": "2018-10-02", "last_synced_at": "2026-09-04T21:56:22.279Z", "location_count": 58, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Escondido, California + 46 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01907854" }, { "nct_id": "NCT02576288", "title": "Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atherosclerosis", "Inflammation" ], "interventions": [ { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 21, "start_date": "2016-01", "completion_date": "2017-12-31", "has_results": false, "last_update_posted_date": "2019-07-17", "last_synced_at": "2026-09-04T21:56:22.279Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02576288" }, { "nct_id": "NCT01741103", "title": "Sitagliptin in Type I Diabetic Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Type I" ], "interventions": [ { "name": "sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2011-06", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2022-03-24", "last_synced_at": "2026-09-04T21:56:22.279Z", "location_count": 1, "location_summary": "Williamsville, New York", "locations": [ { "city": "Williamsville", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01741103" }, { "nct_id": "NCT01701973", "title": "Effect of DPP4 Inhibition on Growth Hormone Secretion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Pegvisomant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "L-NMMA", "type": "DRUG" }, { "name": "Exendin 9-39", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 44, "start_date": "2013-01", "completion_date": "2017-05", "has_results": true, "last_update_posted_date": "2018-05-29", "last_synced_at": "2026-09-04T21:56:22.279Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01701973" }, { "nct_id": "NCT00976937", "title": "24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Lixisenatide Placebo", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Sitagliptin Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 319, "start_date": "2009-08", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-09-04T21:56:22.279Z", "location_count": 21, "location_summary": "Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Paramount", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00976937" }, { "nct_id": "NCT02697253", "title": "Mechanisms Underlying Predictors of Success From Obesity Surgery", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Exendin 9-39 and Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2016-01", "completion_date": "2021-07-29", "has_results": false, "last_update_posted_date": "2022-11-15", "last_synced_at": "2026-09-04T21:56:22.279Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02697253" }, { "nct_id": "NCT00749190", "title": "BI 10773 add-on to Metformin in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "BI 10773", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 495, "start_date": "2008-08", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-13", "last_synced_at": "2026-09-04T21:56:22.279Z", "location_count": 19, "location_summary": "Chula Vista, California • Mission Viejo, California • Pasadena, California + 15 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Spring Valley", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00749190" } ] }